UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. __)*
Andrx Corporation
--------------------------------------
(Name of Issuer)
Common Stock, Par Value $.001 per share
--------------------------------------
(Title of Class of Securities)
03455110
--------------------------------------
(CUSIP Number)
Not Applicable
--------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|_| Rule 13d-1(b)
|X| Rule 13d-1(c)
|_| Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this page shall not be deemed to be
"filed" for the purpose of Section18 of the Securities Exchange Act of 1934
("Act") or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the Notes).
<PAGE>
Cusip 03455110 Page 2 of 4 Pages
13G
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
S.S. OR IRS IDENTIFICATION NO. OF ABOVE PERSON
Watson Pharmaceuticals, Inc. ("Watson")
95-3872914
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ___
Not Applicable (b) ___
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
a Nevada corporation
- --------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 4,977,738
-----------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY -0-
-----------------------------------------------------
EACH 7 SOLE DISPOSITVE POWER
REPORTING 4,977,738
-----------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH -0-
- --------------------------------------------------------------------------------
9 AGGREGATE AMMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,977,738
- --------------------------------------------------------------------------------
10 CHECK THE BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES *
Not Applicable
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
15.8%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILING
<PAGE>
Cusip 03455110 Page 3 of 4 Pages
Schedule 13 G (Cont.)
Item 1(a)- Name of Issuer: Andrx Corporation
Item 1(b)- Address of Issuer's Principal Executive Offices:
4001 SW 47th Avenue Suite 201 Fort Lauderdale, FL 33314
Item 2(a)- Name of Person Filing: Watson Pharmaceuticals, Inc.
Item 2(b)- Address of Principal Business Office:
311 Bonnie Circle
Corona, CA 92880
Item 2(c)- Citizenship: Nevada, USA (Place of Incorporation)
Item 2(d)- Title of Class of Securities: Common Stock
Item 2(e)- Cusip Number: 03455110
Item 3- This statement is being filed pursuant to Rule 13d-1(c).
Item 4(a)- Amount beneficially owned: 4,977,738
Item 4(b)- Percent of Class: 15.8%
Item 4(c)- _____ Number of Shares to which Watson has:
(i)--sole power to vote or to direct the vote: 4,977,738
(ii)-shared power to vote or to direct the vote: -0-
(iii)sole power to dispose or to direct the disposition of: 4,977,738
(iv)-shared power to dispose or to direct the disposition of: -0-
Item 5 - Ownership of Five Percent or Less of a Class: Not Applicable
Item 6 - Ownership of More than Five percent on Behalf of Another Person:
Not applicable
<PAGE>
Cusip 03455110 Page 4 of 4 Pages
Schedule G (Cont.)
Item 7- Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on By the Parent Holding Company: Not
Applicable
Item 8- Identification and Classification of Members of the Group: Not
Applicable
Item 9- Notice of Dissolution of Group: Not Applicable
Item 10- Certification:
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired in the ordinary course of
business and were not acquired for the purpose of and do not have the effect of
changing or influencing the control of the issuer of such securities and were
not acquired in connection with or as a participant in any transaction having
such purposes or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Date: December 2, 1999
WATSON PHARMACEUTICALS, INC.
/ S / Robert C. Funsten
---------------------------------
By: Robert C. Funsten
Senior Vice President,
General Counsel and Secretary
